explore -WSS

explore

author：knowledge 2025-09-29 22:46:09 - browse：726

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： 'The boss' wants server deleted: New allegations emerge in Trump indictment

WSS

FDA authorizes Novavax’s updated Covid

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Colorectal cancer study finds potential in overlooked immune cell

FDA panel signals lack of confidence in Amgen cancer drug data

Marc Tessier

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

focus

explore

entertainment

Jerome Adams on the need for new antivirals for Covid

Interest rates are at a 22

Peter Hotez and the public health issue of online harassment

Bristol 'take

Anesthesiologist group: stop taking Ozempic before surgery

VC firm RA Capital starts a new synthetic biology incubator

Medical leaders decry Supreme Court decision on affirmative action

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Colorectal cancer study finds potential in overlooked immune cell

knowledge

Will biotech layoffs continue through 2023?

An outrageous hospital charge: I paid $710 for an hour of babysitting

Timeline: Special counsel's probe into Trump's handling of classified documents

Stroke deaths set to near 10 million globally by 2050

Behind warning on Apellis’s eye drug lies a conflict of interest

Trump allegedly attempted to have surveillance video deleted: Special Counsel

leisure time

explore

knowledge

leisure time